GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Float Percentage Of Total Shares Outstanding

CHRO (Channel Therapeutics) Float Percentage Of Total Shares Outstanding : 77.11% (As of May. 03, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Channel Therapeutics's float shares is 4.70 Mil. Channel Therapeutics's total shares outstanding is 6.10 Mil. Channel Therapeutics's float percentage of total shares outstanding is 77.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Channel Therapeutics's Insider Ownership is 18.09%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Channel Therapeutics's Institutional Ownership is 0.41%.

Channel Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Channel Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=4.70/6.10
=77.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Channel Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
MTVA CYCN PMCB SLXN TSBX INTS CTXR APRE TRAW HCWB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Website
https://www.channeltherapeutics.com
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.